Colorectal cancer (CRC) is a leading cause of cancer death worldwide; nearly 5 800 000 individuals died of the disease in 2002 (Walt, 2004) . In spite of recent advances in diagnosis and therapeutic strategies, prognosis for patients with advanced tumors remains poor because multiple affected lymph nodes and/or distant metastases are unlikely to be completely curable by surgery.
Standardized regimens for advanced or recurrent disease, which involve combinations of anticancer drugs such as 5-fluorouracil (5-FU), cisplatin, leucovorin, and irinotecan, are only effective in 20-30% of cases (Douillard et al., 2000; Saltz et al., 2000) , and those drugs often evoke highly adverse reactions, being poorly tolerated by some patients and sometimes even fatal. Therefore, effective agents for chemo-or immunotherapy are eagerly sought. To achieve that goal, it is essential that the molecular mechanisms involved in colorectal carcinogenesis be better understood.
Recent progress in revealing mechanisms underlying some neoplasms has opened a new page in terms of strategies for developing novel therapeutic drugs. For example, STI-571, a tyrosine kinase inhibitor that blocks kinase activity of the bcr-abl fusion protein, can effectively treat cases of chronic myelogenous leukemia in which constitutive activation of bcr-abl tyrosine kinase plays a crucial role in transformation of leukocytes (O'Dwyer and Druker, 2000) . STI-571 is also effective against gastrointestinal stromal tumors where activating mutations in the c-kit oncogene are a tumorigenic factor. Gefetinib, a specific inhibitor of the EGFR tyrosine kinase, has brought about a drastic improvement in the treatment of non-small-cell lung cancers (Gridelli et al., 2003) . Trastuzumab, a monoclonal antibody to the HER2/neu receptor that is overexpressed in approximately 30% of breast cancers, has improved clinical response and overall survival of many breast-cancer patients (Molina et al., 2001) . Since these drugs are designed to suppress oncogenic activity of specific gene products involved in carcinogenesis, the products of other genes that are specifically expressed in cancer cells and involved in the growth or survival of cancer cells also represent promising targets for development of new anticancer agents.
Earlier, to uncover mechanisms underlying CRC and identify novel target molecules for development of anticancer drugs, we analysed expression profiles of colorectal tumors by means of a cDNA microarray representing 23 040 genes, and had identified a number of genes that were upregulated in the cancer cells (Lin et al., 2002) . In this study, we focused on a gene corresponding to Hs.14559 (http://www.ncbi.nlm.nih. gov/UniGene/), annotated as C10orf3 (chromosome 10 open reading frame 3). Subsequent quantitative realtime (RT)-PCR confirmed elevated expression of C10orf3 in all nine clinical CRC samples we examined ( Figure 1a and Table 1 ). On multipletissue Northern blots using the C10orf3 cDNA as a probe, we detected a 2.7-kb transcript that was abundantly expressed in the testis and to a lesser degree in the small intestine, colon, thymus, placenta, pancreas and stomach (Figure 1b) . Expression of this transcript was not detectable in the other 16 tissues examined. Since the assembled cDNA sequence of C10orf3 in the NCBI database was shorter than the 2.7-kb transcript, we predicted exon-like sequences from the human genome database using GENSCAN • heart
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• small intestine Figure 1 (a) Expression of C10orf3 in additional nine CRCs evaluated by quantitative RT-PCR using TaqMan assay. Relative expression ratio of C10orf3 in tumor to corresponding noncancerous tissue is illustrated in the histogram. RNA extraction, cDNA synthesis, and TaqMan assay were carried out as described elsewhere (Obama et al., 2005) . Primer sequences were (for C10orf3) forward, 5 0 -TCCGAAAAGCAAGAAATCAAATAA-3 0 , reverse, 5 0 -GATGGCAAACTCATGAAGCTGTT-3 0 , and probe, C10orf3 in the growth of human colon tumor M Sakai et al a partial conserved sequence of an SMC domain between codons 53 and 405, or a partial myosin class II heavy chain domain between codons 20 and 435. A homology search with the predicted amino-acid sequence identified several homologous proteins in mouse (GenBank Accession Number AK028216.1), rat (GenBank accession number NM_001025646.1), chicken (GenBank Accession Number XP_421675.1), and Drosophila (GenBank Accession Number NM_165213.2), which, respectively, shared 75, 76, 52, and 23% identity with human C10orf3.
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We prepared polyclonal antibody to C10orf3 and examined by Western blotting its presence in coloncancer cell lines SW480, SW948, HCT116, HT29, HCT116, LoVo, and DLD1. The results showed a 54-kDa band corresponding to the predicted size of the C10orf3 protein as well as an additional 59 kDa band ( Figure 2a ). To test whether the 59-kDa band represented a form of C10orf3 modified by phosphorylation, we treated the cellular extracts with l-phosphatase before immunoblotting. Since the 59-kDa band did not appear after phosphatase treatment, we judged that C10orf3 was phosphorylated only in living cells. To investigate the subcellular location of C10orf3, we carried out fluorescent immunohistochemical staining in SW480 and HCT116 cells. The protein appeared mainly in cytoplasm ( Figure 2b ). To assess expression of C10orf3 protein in cancerous tissues, we carried out Western blotting using whole-cell extracts from 15 CRC specimens and the corresponding noncancerous mucosae ( Figure 2c ). The intensities of C10orf 3 and b-actin bands in the Western blots were quantified using the chemiluminescent gel imaging system, and ratios of C10orf3 in tumor to noncancerous mucosa were calculated after the normalization with b-actin expression. Among the 15 cases, nine tumors (patients 3, 6, 9, 10, 11, 12, 13, 14, and 15) showed elevated C10orf3 protein more than twofold (Table 1 and Figure 2c ). We further performed immunohistochemical staining of C10orf3 in the 15 cancer tissues and an additional 13 adenomas of the colon. Positive C10orf3 staining was observed in all 15 cancers, mainly in the cytoplasm, and the intensity of staining was stronger than that in corresponding noncancerous epithelial cells (Table 1 and Figure 2d , upper panel). Although noncancerous epithelial cells in the mucosa were weakly stained with the antibody, no significant difference of staining was observed among the noncancerous cells. Enhanced C10orf3 expression was also noted in 11 of the 13 adenomas (premalignant lesions of the colon) including Cell extracts (20 mg each) were incubated with or without 800 units of l-phosphatase (New England Bio Labs) in the presence of 2 mM Mn 2 þ at 301C for 30 min, and proteins were separated by 10% SDS-PAGE. A polyclonal antibody to C10orf3 was purified from the sera of rabbits inoculated with recombinant His-tagged C10orf3 protein that was purified from Escherichia coli bacterial cultures in a manner described elsewhere (Shimokawa et al., 2003) . To explore the function of C10orf3 further, we used a fluorescent 2D-gel electrophoretic assay to search for proteins that would interact with C10orf3. We transfected HEK293 cells with a plasmid expressing Flagtagged C10orf3 protein, extracted proteins from the cells, and carried out immunoprecipitation using antiFlag antibody. The immunoprecipitants were labeled with Cy5, while immunoprecipitants with anti-Flag antibody from cells transfected with control plasmids were labeled with Cy3. Equal amounts of Cy5-and Cy3-labeled proteins were subjected to 2D-gel electrophoresis. We identified four Cy5-specific spots and analysed the proteins using tandem mass spectrometry (data not shown). Among the four proteins, three peptide sequences were successfully determined; these sequences corresponded to Programmed Cell Death 6 Interacting Protein (PDCD6IP), FLJ13969 protein, and Tumor Susceptibility Gene 101 protein (TSG101). Using antiFlag antibody, we immunoprecipitated extracts from COS7 cells transfected with pCMV-C10orf3-Flag, with or without pCAGGS-TSG101-HA. Western blot analysis confirmed that HA-tagged TSG101 co-immunoprecipitated from cells transfected with pCAGGS-TSG101-HA, but not from cells transfected with pCAGGS-mock-HA (Figure 3a, first panel) . Conversely, immunoprecipitation with anti-HA antibody coimmunoprecipitated Flag-tagged C10orf3 from cells with pCMV-C10orf3-Flag, but not those with pCMVmock-Flag (Figure 3a, third panel) . These results confirmed that interaction took place between C10orf3 and TSG101 in vivo.
To confirm their interaction, we cotransfected HEK293 cells with pCAGGS-TSG101-3 Â Flag in combination with or without pcDNA3.1-C10orf3-Myc/ His, and carried out immunohistochemical staining using anti-FLAG antibody. Although we were able to detect Flag-tagged TSG101 in the cytoplasms in the absence of exogenous C10orf3, we detected no signal when cells were transfeced with both plasmids (data not shown). Immunoblot analysis using extracts from the cells revealed that Flag-tagged TSG101 was significantly reduced in the presence of C10orf3 compared to the absence of C10orf3 (Figure 3b ), suggesting that C10orf3 may decrease TSG101 protein. Interestingly, semiquantitative RT-PCR using RNA from the cells demonstrated unchanged expression of TSG101 mRNA by coexpression with C10orf3 (Figure 3b ). Taking the interaction between C10orf3 and TSG101 together, C10orf3 may downregulate TSG101 protein through destabilization of TSG101. Since TSG101 is involved in the suppression of transformation (Li and Cohen, 1996) , elevated expression of C10orf3 may confer oncogenic activity to tumor cells through the downregulation of TSG101. This hypothesis needs further investigation.
We designed plasmids to express siRNAs for C10orf3 (psiH1BX-C10orf3-A and psiH1BX-C10orf3-B), and examined them for potential knockdown effects in cancer cells. Transfection of SW480 and HCT116 cells with psiH1BX-C10orf3-B significantly reduced C10orf3 expression, but neither psiH1BX-C10orf3-A nor the control plasmid (psiH1BX-EGFP) affected the expression level (Figure 4a and b) . We then examined viability of SW480 and HCT116 cells that had been transfected with these plasmids and cultured in media containing appropriate concentrations of geneticin. Cultures transfected with C10orf3-B siRNA showed significantly reduced numbers of viable cells compared to those transfected with EGFP siRNA, and the number of viable cells in C10orf3-A siRNA-transfected cultures was similar to that in EGFP siRNA-transfected cultures (Figure 4a C10orf3 in the growth of human colon tumor M Sakai et al of colon-cancer cells. To clarify whether the growth suppression is associated with induction of apoptosis or not, we treated SW480 cells with siRNAs, and carried out FACS analysis. Expression of si-C10orf3-B significantly increased subG1 cells (18.3%, Po0.01) compared to those treated with si-EGFP (9.8%) or si-C10orf3-A (9.3%). These data suggested that suppression of C10orf3 might lead to induction of apoptosis ( Figure  4c and d) .
We have documented here the up-regulation of C10orf3 in the majority of CRCs we examined. Earlier expression-profile analyses using microarrays had shown that C10orf3 expression was also elevated in eight of 13 gastric cancers (Hasegawa et al., 2002) , three of four hepatocellular carcinomas (Okabe et al., 2001) , 22 of 25 lung cancers (Kikuchi et al., 2003) , 11 of 12 pancreatic cancers (Nakamura et al., 2004) , and 32 of 44 breast cancers examined (Nishidate et al., 2004) . Therefore, overexpression of the C10orf3 gene is not specific to CRC but is associated with a wide range of human cancers. Furthermore, in the experiments noted here, C10orf3 protein was frequently augmented in pre-malignant lesions of the colon, an indication that enhanced expression of the gene can occur in an early step of tumorigenesis; that is, C10orf3 may play a role not in the progression of cancers but in the development of tumors. Hence, enhanced C10orf3 may associate with features common to benign and malignant tumors, such as hyperplastic growth or prolonged survival.
The SMART program predicted an AAA domain in the C10orf3 protein. Generally, AAA domains A plasmid vector (psiH1BX) expressing short interfering RNA (siRNA) and a control plasmid expressing siRNA to EGFP (psiH1BX-EGFP) were prepared as described previously (Shimokawa et al., 2003) . Plasmids expressing C10orf3-siRNA were prepared by cloning the following double-stranded oligonucleotides into the psiH1BX vector: 5 0 -TCCCCATCTGGAA GATGATAGGCTTCAAGAGAGCCTATCATCTTCCAGATG-3 0 and 5 0 -AAAACATCTGGAAGATGATAGGCTCTCTTGAA GCCTATCATCTTCCAGATG-3 0 (psiH1BX-C10orf3-A) and 5 0 -TCCCGGAGAGACTGAAAACAGAGTTCAAGAGACTCTG TTTTCAGTCTCTCC-3 0 and 5 0 -AAAAGGAGAGACTGAAAACAGAGTCTCTTGAACTCTGTTTTCAGTCTCTCC-3 0 (psiH1BX-C10orf3-B). These plasmids were transfected into SW480 and HCT116 cells using Nucleofector reagent according to the supplier's recommendations (Amaxa). Semiquantitative RT-PCR experiments using total RNA that was extracted from the cells 48 h after transfection. In another experiment, cells were transfected with psiH1BX-C10orf3-A, psiH1BX-C10orf3-B, or psiH1BX-EGFP using FuGENE reagent (Roche) and cultured in the presence of appropriate concentrations of geneticin (G418) for 10 days. Viability of the transfected cells was examined by a cell-counting kit (Dojindo Laboratories). The data were subjected to analysis of variance (ANOVA) and Scheffe's F-tests. C10orf3 in the growth of human colon tumor M Sakai et al contain one or two copies of a well-conserved cassette of 230-250 amino acids encompassing Walker A and B motifs (Neuwald et al., 1999) ; however, C10orf3 contained neither of these motifs, so it is not likely to be an actual member of the AAA family. On the other hand PDB1i84, an alternative domain predicted by SMART, is a motif conserved in contractile proteins including smooth muscle myosin heavy chain, and our BLAST search consistently identified a partial myosin II heavy chain domain in C10orf3. The conserved-domain search also identified part of a structural maintenance of chromosomes (SMC) domain. SMCs are generally comprised of a N-terminal ATP binding cassette (ABC) containing a Walker A motif; a C-terminal ABC containing an Walker B motif, and a central conserved-arginine finger region; the three regions are connected by two long coiled-coil motifs (Jessberger, 2002) . SMC proteins play crucial roles in the chromatin structure, through ATPase activity of the two ABCs (Jessberger, 2002) . However, the homologous region of C10orf3 localized in the N-terminal coiled-coil motif of the SMC domain, and did not include ABCs. These data suggest that C10orf3 lacks ATPase activity but could still function as a contractile protein.
TSG101 was originally identified as a tumor suppressor whose decreased expression transformed NIH3T3 cells and increased the metastasizing potential of SL6 cells derived from NIH3T3 in athymic mice (Li and Cohen, 1996) . Although aberrant transcripts of TSG101 had been identified in a variety of human cancers including breast and prostate, these transcripts were later found to be alternatively spliced forms (Lee and Feinberg, 1997; Sun et al., 1997) . The tumor-suppressive role of TSG101 has been controversial, moreover, since Wagner et al. (2003) reported that TSG101 is essential for growth, proliferation, and survival of cells in normal embryonic and adult tissues. In addition, downregulation of TSG101 by short interfering RNA resulted in partial arrest of the cell cycle and decreased proliferation of prostate-and breast-cancer cells (Zhu et al., 2004) . TSG101 protein colocalizes with microtubular organizing centers and mitotic spindles during mitosis (Xie et al., 1998) . Injection of anti-TSG101 antibody results in nuclear, microtubule, and mitotic-spindle abnormalities (Xie et al., 1998; Zhong et al., 1998) , suggesting that TSG101 plays an essential role in mitosis. However, TSG101 plays other roles as well, for example in ubiquitination (Garrus et al., 2001) , transcriptional regulation (Li et al., 2001) , and endosomal trafficking (Bishop and Woodman, 2001 ). Since we have shown here that C10orf3 interacts with TSG101, elevated expression of C10orf3 may play a crucial role in the proliferation of cancer cells by modulating TSG101. Given the localization of TSG101 in mitotic spindles and the nature of conserved sequences in C10orf3, the latter may exert an essential role in mitosis in association with TSG101.
Northern blotting revealed tissue-specific expression of C10orf3 in normal organs, that is, abundant expression in the testis; low levels of expression in the small intestine, thymus, and placenta; very low levels in the colon, stomach and pancreas; and undetectable levels in the heart, liver, lung, kidney and bone marrow. In terms of development of anticancer drugs targeting C10orf3, since the gene is not expressed in organs that associate directly with life, inhibition of C10orf3 should not have seriously adverse consequences except in the digestive tract.
We have demonstrated that expression of C10orf3 is elevated in a wide range of human cancers, and is absent or weak in normal tissues except for the testis. Importantly, in our experiments suppression of C10orf3 expression significantly retarded the growth of cancer cells; therefore, C10orf3 may be a good candidate for molecular targeting to treat human cancers. Further investigation will be necessary for disclosing the mechanism(s) by which C10orf3-siRNA retards growth of cancer cells, and for revealing the physiological role of the protein in normal testis. The data provided here should contribute to a better understanding of human carcinogenesis and to the development of novel therapeutic strategies.
